Skip to content
Screener

United Therapeutics UTHR Cash Flow Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
$333M+7.6%$274.9M-14.7%$364.3M+20.9%$338.7M+9.6%$309.5M+11.3%
$24.2M+14.7%$22.6M+14.1%$22.8M+15.7%$21.9M+14.7%$21.1M+12.8%
$43.4M+14.8%$33.9M+6.6%$39M+44.4%$39.1M-6.2%$37.8M-23.9%
$313.6M+63.6%$463.3M+0.5%$346.2M+1.5%$562.1M+49.0%$191.7M-17.4%
$108M+73.6%$100.8M+34.6%$172.9M+99.4%$210.5M+175%$62.2M+37.9%
$87.5M+129%$743.7M+552%-$227.6M-$299.9M
$1.5B$0$1B$0
$50M$50M$50M
$0-100%$0-100%$400M+300%
-$1.48B-1,483%$0+100%-$956M-1,391%-$198.6M-314%
$523.5M+271%-$277.4M-237%-$253M-228%-$306.8M-394%
$205.6M+58.8%$362.5M-6.2%$173.3M-31.9%$351.6M+16.9%$129.5M-30.8%

FAQ

How much cash does United Therapeutics generate?
United Therapeutics (UTHR) generated $1.7B in operating cash flow over the trailing twelve months.
What is United Therapeutics's free cash flow?
After $592.2M of capital expenditures, United Therapeutics's free cash flow was $1.1B over the trailing twelve months, up 2.1% year over year.
Where does United Therapeutics's cash flow data come from?
Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.